Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160826 | 1.00 | HTT (0.50) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL1649114 | 1.00 | HTT (0.50) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL13160820 | 1.00 | HTT (0.50) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL13160815 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL11983605 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL11983673 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL13160830 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL13160831 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL11983500 | 0.98 | HTT (0.49) | HTTL3MBTL1KDM4ETSHRATM | |
| SCHEMBL12362394 | 0.95 | L3MBTL1 (0.46) | HTTL3MBTL1KDM4ETSHRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304477-B2 | Liquid oxyalkylene bridged bis- and Tris-phosphite ester mixtures | BASF SE (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304477-B2 | Liquid oxyalkylene bridged bis- and Tris-phosphite ester mixtures | BASF SE (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304477-B2 | Liquid oxyalkylene bridged bis- and Tris-phosphite ester mixtures | BASF SE (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2313421-B1 | LIQUID OXYALKYLENE BRIDGED BIS- AND TRIS-PHOSPHITE ESTER MIXTURES | BASF SE (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2313421-B1 | LIQUID OXYALKYLENE BRIDGED BIS- AND TRIS-PHOSPHITE ESTER MIXTURES | BASF SE (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20110196082-A1 | STORAGE-STABLE AQUEOUS EMULSIONS AND LIQUID BLENDS WITH LOW VISCOSITY AS STABILIZERS | BASF SE (DE) | 2011-08-11 | — | — | US | disclosed |
| EP-2313421-A2 | LIQUID OXYALKYLENE BRIDGED BIS- AND TRIS-PHOSPHITE ESTER MIXTURES | BASF SE (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-20100240810-A1 | Liquid Oxyalkylene Bridged Bis- andTris-Phosphite Ester Mixtures | KING ROSWELL E | 2010-09-23 | — | — | US | disclosed |
| US-20100240810-A1 | Liquid Oxyalkylene Bridged Bis- andTris-Phosphite Ester Mixtures | KING ROSWELL E | 2010-09-23 | — | — | US | disclosed |
| US-20100240810-A1 | Liquid Oxyalkylene Bridged Bis- andTris-Phosphite Ester Mixtures | KING ROSWELL E | 2010-09-23 | — | — | US | disclosed |
| WO-2010003809-A2 | LIQUID OXYALKYLENE BRIDGED BIS- AND TRIS-PHOSPHITE ESTER MIXTURES | BASF SE (DE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010003809-A2 | LIQUID OXYALKYLENE BRIDGED BIS- AND TRIS-PHOSPHITE ESTER MIXTURES | BASF SE (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240810-A1 | Liquid Oxyalkylene Bridged Bis- andTris-Phosphite Ester Mixtures | EPB41, PHOSPHO1, TNS4 | HTT 4337/4885L3MBTL1 550/4885KDM4E 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.